WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company, announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023, at 1:00 PM ET. The program will feature the Company’s lead drug candidate, istaroxime, a first-in-class, dual-acting agent, being developed to treat cardiogenic shock and acute decompensated heart failure. Istaroxime is designed to improve systolic contraction and diastolic relaxation of the heart.
The event will feature insights from John Teerlink, MD, Director of Heart Failure and of the Echocardiography Laboratory, San Francisco Veterans Affairs Medical Center and an active leader in US and European Heart Failure medical associations. Dr. Teerlink has been the principal investigator in many of the largest heart failure and cardiogenic shock studies and recently served a four-year term on the FDA’s Cardiovascular and Renal Advisory Committee. Dr. Teerlink will discuss the unmet medical need and current treatment landscape for patients suffering from cardiogenic shock and severe heart failure – a condition with high mortality, morbidity and unmet need and put the unique profile of istaroxime and its data into perspective.
Members of Windtree’s leadership team will present istaroxime early cardiogenic shock study data and provide insight into the istaroxime expanded development strategy and planned near-term milestones. Additionally, strategy related to acute heart failure, the follow-on oral, SERCA2a activators and business development will be discussed.
A live question and answer session will follow the presentations. The session will be available for replay on the Company’s website www.windtreetx.com. To register for the event, please click here.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.